Long Read Analysis in Spinal Muscular Atrophy - LOREASI
Recruiting now · Not applicable
Conditions studied: Spinal Muscular Atrophy (SMA)
In brief
Spinal Muscular Atrophy (SMA) is a severe neuromuscular disease caused by deletion of the SMN1 gene, with the most severe form leading to death in children without treatment. Genetic counselling to detect couples where both partners are carriers is particularly important. In some countries, preconception screening is offered. However, some carriers escape detection due to the existence of two copies of the SMN1 gene side-by-side (2+0 genotype). Currently, no molecular genetic methods used for diagnostic purposes can detect these 2+0 genotypes, which pose a significant challenge in genetic counselling. This study aims to use new technologies based on the analysis of ultra-long molecules to detect side-by-side duplications of the SMN1 gene to detect heterozygous subjects not identified by current techniques and improve genetic counselling.
Key facts
- Study ID
- NCT07332702
- Run by
- University Hospital, Rouen
- People needed
- 27
- Starts
- 2025-05-15
- Expected to finish
- 2027-01-15
- Last updated by the study team
- 2026-01-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult Subject:
- Subject with either:
- 1 or 3 copies of the SMN1 gene (control group) and a variable number of copies of the SMN2 gene
- 2 copies of the SMN1 gene in cis (2+0 genotype) (test group)
- Affiliation to French health insurance
- Signed consent form
You may not qualify if…
- Pregnant or breastfeeding women
- Individuals deprived of liberty by an administrative or judicial decision, or those under guardianship or curatorship
Where it is running
- CHU Rouen — Rouen, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.